Neurosoft Bioelectronics, a Geneva-based neurotechnology company developing stretchable brain-computer interfaces, has raised an oversubscribed $7.5 million seed round led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, Connecticut Innovations, and others.
The company said the funding will support near-term milestones including demonstrating minimally invasive deployment in human patients and pursuing US commercialization of its first brain interface. It also plans to use the capital to accelerate development of a cortical foundation model for next-generation brain-computer interfaces.
Neurosoft said its platform has already been tested in 10 patients. The company, which is building soft, stretchable electrodes designed to access the full cortex without penetrating brain tissue, said total funding to date now exceeds $20 million.
The company said the funding will support near-term milestones including demonstrating minimally invasive deployment in human patients and pursuing US commercialization of its first brain interface. It also plans to use the capital to accelerate development of a cortical foundation model for next-generation brain-computer interfaces.
Neurosoft said its platform has already been tested in 10 patients. The company, which is building soft, stretchable electrodes designed to access the full cortex without penetrating brain tissue, said total funding to date now exceeds $20 million.